Back on June 15, 2023, I published the surprising announcement that CMS was covering an LDT PSA-related test under the NCD for prostate screening. This would be unusual, because of CMS's preference (both stated, and observed) for only handling FDA-authorized tests under NCDs.
The wheels turn. On August 3, 2023, CMS issued a transmittal - CR 13278 - which retracts coverage for test. Test 0359U is no longer covered under the NCD as a national prostate screening test.
